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New Understanding of Algae
Within one week, British botanist Brian A.
Whitton received two phone calls about
cyanobacteria in local reservoirs-one caller
wanted to know how to eradicate a poten-
tially toxic bloom, the other wanted advice
on marketing a related species as a health
food. The anecdote, shared by Whitton at
the 4th International Conference on Toxic
Cyanobacteria, held 27 September-1
October 1998 at the Duke University
Marine Laboratory in Beaufort, North
Carolina, points to the complexities in
understanding such organisms; some con-
tain potent toxins and others promise
health and therapeutic benefits.
An unprecedented number of labora-
tories worldwide are studying cyanobacte-
ria, also known as blue-green algae, and
participation at the September conference
ballooned from early predictions, said
conference cochair Wayne Carmichael, a
cyanobacteria researcher and professor of
aquatic biology and toxicology at Wright
State University in Dayton, Ohio.
Microcystins were a common theme
among many presentations. Toxic sub-
stances manufactured in the cells of some
cyanobacteria, microcystins have been
blamed for the liver failure and subsequent
death of 75 dialysis patients at a clinic in
Caruaru, Brazil, in 1996, said Carmichael.
Other patients suffered nausea, vomiting,
headache, and visual disruption, including
blindness. The poisonings occurred in
spite of water treatment methods in place
that should have removed the contami-
nants from the clinic's water supply.
Although microcystins have also been sus-
pected in dialysis clinic deaths in Portugal,
the Brazil fatalities were the only ones to
date documented by analyses of blood
serum and tissue samples.
Could this scenario occur in the
United States or other developed nations?
Cyanobacteria appear around the world in
freshwater lakes and brackish waterways;
some even tolerate seawater, and a few are
terrestrial. Aquatic blooms flourish in the
presence of increased nutrients, especially
phosphorus. Carmichael reminded confer-
ence participants that water treatment pro-
cedures are only as good as the upkeep that
accompanies them.
"We tend to pride ourselves on the fact
that we have better water treatment [in the
developed world]," he said. "But if you
look at the water treatment process in
place here, it's not much different than any
other place in the world. I'm told that in
most dialysis clinics in the United States,
it's not a fail-safe procedure, that it needs
to be maintained properly."
In a study of selected water utilities
throughout the United States and Canada
during 1996 and 1997, Carmichael and his
colleagues found microcystins in 65% of
water samples that had not undergone treat-
ment. A third of the positive samples regis-
tered levels of microcystins in excess of the
recently adopted World Health
Organization (WHO) drinking water stan-
dard of 1.0 jig/1 of total microcystin. In a
few cases, treated water samples contained
microcystin levels higher
than the MHO guideline.
Cyanobacteria
species number in the
thousands, and it is not
known what percentage
produce toxins. Besides
microcystins, which
attack the liver, other
cyanotoxins have been
identified that affect the
nervous system and
cause skin rashes. For
more than a century,
blue-green algae have been implicated in
the deaths of livestock and other animals
that drink contaminated water. People
have historically avoided drinking from
and bathing in lakes and other waters
laden with surface scum, primarily because
the algae produce a bad taste and odor.
"Decreasing water quality throughout
the world means that these blooms are pre-
sent more often and for a longer duration,
and people are using marginal water sup-
plies more than they did in the past. They
are forced to bathe in a bloom or to use
water from a bloom," says Carmichael.
"We are now starting to see acute poison-
ings, contact irritations, accidental inges-
tion, and low-dose exposure [that may
result in] liver cancer."
Ian Falconer, a professor at the
University ofAdelaide Medical School in
Australia, said reports of contaminated
drinking water are pushing blue-green
algae into the spotlight. "Lead, arsenic, and
things like that are known environmental
contaminants," Falconer said, "where
cyanobacteria have only really become sig-
nificant through eutrophication. There is
an issue everywhere with respect to the
water industry in meeting the WHO
guidelines. The other issue is whether the
most sophisticated treatments, which are
more expensive, are actually [being used]."
Scientists from 35 countries made up
the more than 150 participants at the con-
ference, and presented on a range oftopics
including laboratory toxicity and develop-
mental tests in animals, molecular analysis,
toxin detection, regulation, and ecological
studies. The beneficial aspects ofcyanobac-
teriawere also represented. Whilesuch algae
as Microcystis, Anabaena, and Nodularia
produce chemicals lethal to humans and
animals, some blue-green algae produce
compounds that have anticarcinogenic,
antibacterial, or antifungal properties.
Extracts ofa blue-green algae have pro-
duced the antitumor drug cryptophycin,
which is currently in clinical trials, said
Richard Moore, a professor ofchemistry at
the University of Hawaii in Honolulu.
Blue-green bombshell. Cyanobacteria such as Microcystis aeruginosa (I)
and Nodularia (r) contaminate much ofthe world's watersupplywith tox-
insthatcause serious health effects.
Extracts from a marine blue-green algae
collected in Guam have also exhibited anti-
tumor properties, and appear to be chemi-
cally similar to dolastatin 10, a compound
derived from marine mollusks that is also
undergoing clinical trials as a cancer drug,
Moore said.
Consumption of blue-green algae has
also been touted as a health benefit by the
dietary supplement industry. More than 1
million people in the United States and
Canada consume blue-green algae in cap-
sule or tablet form. Much ofthe product is
harvested from blooms ofAphanizomenon
in Oregon's Klamath Lake. Concurrent
toxic blooms of Microcystis aeruginosa in
1996 prompted consumer concern about
the safety of the product. Health officials
subsequently determined a standard of 1
pg/g (equal to 1 ppm) to be a safe level of
microcystins in supplements, said Duncan
Gilroy, a public health toxicologist with
the Oregon Health Division in Portland.
But 50 of 67 samples obtained from har-
vesters, wholesalers, and retail outlets
exceeded 1 ppm, he said. "We are con-
cerned about people getting exposure to
even low levels ofmicrocystin for the long
term," said Gilroy.
Alzheimer's Disease: A Basis
in Bacteria?
According to a study published in the June
1998 issue of Medical Microbiology and
Immunology, the bacterium Chlamydia
pneumoniaemay be linked with, or possibly
even responsible for, Alzheimer's disease, a
form of dementia that currently affects
approximately 4 million U.S. citizens.
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Brian J. Balin, an associate professor at the
Philadelphia College of Osteopathic
Medicine in Pennsylvania, and Alan P.
Hudson, an associate professor in the
department ofmicrobiology and immunol-
ogy at Wayne State University School of
Medicine in Detroit, Michigan, led what
may prove to be a huge step forwarding in
understanding Alzheimer's. Says Balin,
"We don't have a definite cause yet, butwe
definitely have a potential cause or risk fac-
tor forthe disease."
C. pneumoniae is the cousin of C. tra-
chomatis, which causes both the sexually
transmitted infection commonly known as
chlamydia and trachoma, a form ofblind-
ness. C. pneumoniae is a pervasive bacteri-
um, appearing in 40-70% of adults.
Unlike most other bacteria, C.
pneumoniae can only live inside a
cell and draws its energy from
the cell's supply of adenosine
triphosphate. The bacterium is
spread through sneezing and
coughing, and causes diseases
such as sinusitis and bronchitis.
In studying the relationship
between C. pneumoniae and late-
onset Alzheimer's, Balin and
Hudson used postmortem sam-
ples from various regions of the
brains of patients both with and
without Alzheimer's. From each
sample, the scientists prepared
samples of nucleic acid, which
were screened by polymerase
chain reaction assay for the pres-
ence oftwo C.pneumoniaemarker
genes. Analyses showed that sam-
ples from 17 ofthe 19 brains with
Alzheimer's tested positive for the bacteria,
while only 1 of 19 brain samples without
Alzheimer's testedpositive.
The C. pneumoniae cells were found to
be concentrated in the microglial and
astroglial cells. (The microglia function as
an immune system within the brain, gener-
ating severe inflammation when infected,
while the astroglia promote neuronal cell
maintenance and growth.) The organism
was also found to be concentrated in brain
regions marked by neuropathologies char-
acteristic ofAlzheimer's, such as neurofib-
rillary tangles, composed ofthe cytoskeletal
proteins ofdamaged neurons, and neuritic
senile plaques, caused by the accumulation
of the peptide P-amyloid-believed by
some scientists to be secreted by the
astroglia.
Balin and Hudson think the deposi-
tion and processing of ,B-amyloid may
begin after an initial infection with C.
pneumoniae. "Where you have certain
types ofpathology, that's where you have
accumulation ofthe organism," says Balin.
This raises the possibility that the damag-
ing plaques and tangles may form in
response to infection with C. pneumoniae.
Balin also believes the organism may live
in people's cells for decades, causing a
slow, chronic immune response. By hiding
out in the body, he posits, the bacterium
escapes surveillance as a foreign body.
There maybe additional factors acting in
relationshipwith C.pneumoniae. "Ifeveryone
gets C. pneumoniae, why doesn't everyone
also get Alzheimer's disease?" asks Hudson.
'There are unidentified genetic factors work-
inginrelationshipwith C.pneumoniae." One
possible partner is apolipoprotein E, a serum
protein used in lipid transport. Each person's
DNA contains some combination oftwo of
This is your brain on pesticides? New research suggests exposure to
noetirid-e mav hp linked with Parkinsnn's disease.
five different alleles of apolipoprotein E;
while the APOE4allele occurs in 13-15%
ofthegeneral population, itturns up in 60%
ofAlzheimer's patients. Hudson and Balin
think APOE4may act in conjunction with
C. pneumoniae infection to cause
Alzheimer's. Says Balim, "We have a realistic
mechanism for allowing the organism to
entercelis incertainpeople."
The scientists also performed electron-
and immunoelectron-microscopic studies
on tissue samples from both Alzheimer's
and non-Alzheimer's brains. These studies
also identified C pneumoniae organisms in
the Alzheimer's samples but not in the
non-Alzheimer's samples. Culture studies
ofa subset ofAlzheimer's brain tissues for
C. pneumoniae were strongly positive,
while identical analyses ofnon-Alzheimer's
brain tissues were negative.
One ofthe next steps for the scientists
is to investigate how C. pneumoniae infil-
trates the nervous system. Balin plans to
examine postautopsy brain samples to
determine the earliest stages of late-onset
Alzheimer's and identify whether the
organism is present in those stages. Other
future projects include a cell culture study
to demonstrate which specific cellular
mediators are turned on by the C. pneumo-
niaeorganism, and developing methods for
diagnosing C. pneumoniae infection. The
findings of this research could result in
clinical trials ofantibiotics and antiinflam-
matory agents to treat Alzheimer's in the
near future. Says Balin, "Ifwe can block
the stimulus for inflammation and inflam-
mation itself, we may be able to prevent
damage." At the least, says Hudson, dam-
age could be postponed orameliorated.
Gene-Toxicant Link to
Parkinson's Disease
The combination ofpesticide expo-
sure and a particular genetic trait
may increase the risk that people
with Parkinson's disease will devel-
op dementia. That's the condusion
of a preliminary study conducted
by researchers at the University of
Kansas Medical Center in Kansas
City, Barrow Neurological Institute
in Phoenix, Arizona, and the
Veterans Affairs Puget Sound
Health Care System in Seattle,
Washington. The study, published
in the March-April 1998 issue of
Neuroepidemiology, looked for possi-
ble causes of the dementia that
occurs in about one-fifth of all
Parkinson's Datients.
Parkinson's disease is a brain
disorder that causes trembling, slow
movements, a rigid posture, and an unbal-
anced, shuffling walk. The subjects ofthis
study were 94 patients with Parkinson's
disease, 43 ofwhom had dementia and 51
ofwhom did not. The researchers looked
atvarious environmental, sociodemograph-
ic, and clinical variables, as well as three
suspected gene markers. As in previous
research, they found that lower educational
level, older age at disease onset, and greater
motor impairment were individual risk fac-
tors for dementia. For the first time, they
also showed that patients who had been
exposed to pesticides in the past and who
had a gene known as the CYP 2D629B+
allele were three times more likely to devel-
op dementia than patients who lacked this
combination offactors.
"This study was the first attempt in
Parkinson's disease to see ifwe could iden-
tify interactions between unique genetic
makeups and exposure to environmental
toxins," says coauthor Matthias Kurth,
director of clinical science for Axys
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